



Ministerio
de Salud

Instituto Nacional
de Salud

Decenio de la Igualdad de Oportunidades para mujeres y hombres
"Año de la recuperación y consolidación de la economía peruana"

COMMUNICATION N° 003-2025-DIIS/INS

Publication date: July 18, 2025

Final transition to the REPEC v2 system for the notification of Serious Adverse Events (SAE)

The public is informed that, in accordance with the agreements adopted during the **technical meeting of July 2, 2025** on the notification of EAS and DSUR, it has been arranged that, as of **August 31, 2025**, the **REAS-net** platform will be disabled for the submission of EAS reports and will be enabled only as a historical repository for consultation.

In that sense:

- All **pending EAS** in **REAS-net** must be **completed on that platform** before the indicated deadline.
- From that date onwards, **all notifications of new EAS must be made exclusively through the REPEC v2.0 system**, without exception, including those corresponding to clinical trials initiated before 2021.

Sponsors, OICs, and principal investigators are urged to take the necessary steps to complete the transition within the established timeframe.

For technical inquiries, please contact: jparillo@ins.gob.pe

consultaensayos@ins.gob.pe

Sincerely,

Deputy Directorate of Clinical Trials

Directorate of Research and Innovation in Health – DIIS

National Institute of Health